RNASEL

Summary

RNASEL (ribonuclease L, HGNC:10050) is a protein-coding gene on chromosome 1q25.3, encoding 2-5A-dependent ribonuclease (Q05823). Endoribonuclease that functions in the interferon (IFN) antiviral response.

This gene encodes a component of the interferon-regulated 2-5A system that functions in the antiviral and antiproliferative roles of interferons. The protein is involved in innate immunity and is active against multiple RNA viruses, including the influenza and SARS-CoV-2 viruses. Mutations in this gene have been associated with predisposition to prostate cancer and this gene is a candidate for the hereditary prostate cancer 1 (HPC1) allele.

Source: NCBI Gene 6041 — RefSeq curated summary.

At a glance

• Gene–disease (curated): multisystem inflammatory syndrome in children and adults (Moderate, GenCC) — +1 more curated relationship
• GWAS associations: 2
• Clinical variants (ClinVar): 169 total — 1 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 3
• Druggable target: yes
• MANE Select transcript: NM_021133

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10050
Approved symbol	RNASEL
Name	ribonuclease L
Location	1q25.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000135828
Ensembl biotype	protein_coding
OMIM	180435
Entrez	6041

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000367559, ENST00000539397, ENST00000890859, ENST00000946546

RefSeq mRNA: 1 — MANE Select: NM_021133 NM_021133

CCDS: CCDS1347

Canonical transcript exons

ENST00000367559 — 7 exons

Exon	Start	End
ENSE00000922066	182584081	182584166
ENSE00001445028	182585327	182586970
ENSE00001445029	182589167	182589256
ENSE00001818322	182573634	182575578
ENSE00002328872	182582053	182582258
ENSE00002350700	182581225	182581357
ENSE00002416678	182576256	182576389

Expression profiles

Bgee: expression breadth ubiquitous, 249 present calls, max score 90.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.9815 / max 88.6392, expressed in 1427 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
16158	3.7430	1302
16157	0.7507	390
16159	0.4565	266
16156	0.0313	13

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
amniotic fluid	UBERON:0000173	90.81	gold quality
palpebral conjunctiva	UBERON:0001812	87.85	gold quality
germinal epithelium of ovary	UBERON:0001304	86.15	gold quality
epithelium of nasopharynx	UBERON:0001951	86.02	gold quality
blood	UBERON:0000178	85.78	gold quality
esophagus squamous epithelium	UBERON:0006920	84.49	gold quality
visceral pleura	UBERON:0002401	83.58	gold quality
mucosa of paranasal sinus	UBERON:0005030	83.55	gold quality
jejunal mucosa	UBERON:0000399	83.52	gold quality
parietal pleura	UBERON:0002400	83.30	gold quality
bronchial epithelial cell	CL:0002328	82.94	gold quality
seminal vesicle	UBERON:0000998	82.91	gold quality
corpus epididymis	UBERON:0004359	82.90	gold quality
monocyte	CL:0000576	82.82	gold quality
leukocyte	CL:0000738	82.81	gold quality
tibia	UBERON:0000979	82.78	gold quality
mononuclear cell	CL:0000842	82.64	gold quality
pleura	UBERON:0000977	82.42	gold quality
caput epididymis	UBERON:0004358	81.76	gold quality
granulocyte	CL:0000094	81.47	gold quality
calcaneal tendon	UBERON:0003701	81.44	gold quality
epithelium of esophagus	UBERON:0001976	81.17	gold quality
adrenal tissue	UBERON:0018303	80.83	gold quality
colonic mucosa	UBERON:0000317	80.81	gold quality
rectum	UBERON:0001052	80.30	gold quality
tendon	UBERON:0000043	79.66	gold quality
mucosa of transverse colon	UBERON:0004991	79.65	gold quality
epithelium of bronchus	UBERON:0002031	79.58	gold quality
oral cavity	UBERON:0000167	79.57	gold quality
stromal cell of endometrium	CL:0002255	79.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.35

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): BRCA1, MYC

miRNA regulators (miRDB)

100 targeting RNASEL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-5682	99.89	72.56	1005
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-302A-3P	99.89	71.23	1777

Literature-anchored findings (GeneRIF, showing 40)

• Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. (PMID:11941539)
• Analysis of the RNASEL gene in familial and sporadic prostate cancer. A total of six variants were identified, including one intronic and five exonic changes (three missense and two silent alterations). (PMID:12022038)
• Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome (PMID:12034027)
• physical performance and prediction of 2-5A synthetase antiviral pathway activity in patients with chronic fatigue syndrome. (PMID:12073768)
• in rRNA and small nucleolar RNA maturation, not in telomere elongation inhibition (PMID:12118002)
• A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. (PMID:12145743)
• The variant Arg462Gln has 3X less enzymatic activity than the wildtype and is significantly associated with prostate cancer risk (P=0.007). (PMID:12415269)
• Author reviews the tumor suppressor role of RNase L, proposing that it functions in counteracting prostate cancer by virtue of its ability to degrade RNA, thus initiating a cellular stress response that leads to apoptosis. (PMID:12590567)
• A genome-wide scan of high risk prostate cancer families in North America has demonstrated linkage of a particular marker to chromosme 1q(HPC1). (PMID:12653398)
• polymorphic changes within the RNASEL gene may be associated with familial prostate cancer risk (PMID:12915880)
• JNK and RNase L function in an integrated signaling pathway during the IFN response that leads to elimination of virus-infected cells through apoptosis (PMID:14570908)
• RNASEL may function as a tumor suppressor in prostate cancer. (PMID:14695991)
• does not constitute a major cell defence mechanism against the varicella-zoster virus infection (PMID:15107989)
• Studies report an association between the RNASEL G1385A variant and prostate cancer risk; this variant does not appear to be implicated in the development of breast cancer. (PMID:15330212)
• RNASEL does not have a major role in prostate cancer etiology (PMID:15534086)
• These results indicated that the ankyrin-repeat domain of RNase L constricts its structure by binding of 2-5A. This observation suggests a revised model of the 2-5A-induced activation of RNase L. (PMID:15849753)
• Human translation termination factor eRF3/GSPT1 is an interacting partner of RNase L. (PMID:15908960)
• results suggest that RNASEL variants Glu265X and Arg462Gln may contribute to the tumorigenesis of sporadic and familial pancreatic cancer (PMID:15981205)
• Single nucleotide polymorphisms associated with hereditary prostate cancer. (PMID:16114055)
• Hepatitis c virus polyprotein expression caused a severe cytopathological effect in human cells as a result of inhibition of protein synthesis and apoptosis induction, triggered by the activation of the IFN-induced enzymes PKR and RNase L systems. (PMID:16156900)
• androgen receptor and the interferon-activated RNase L interact with each other in a ligand-dependent manner (PMID:16166078)
• 2’-5’-linked oligoadenylate activation of RNase L produces a remarkable stimulation of transcription (>/=20-fold) for genes that suppress virus replication and prostate cancer. (PMID:16203993)
• characterization of 2’,5’-linked oligoadenylate binding determinant of human RNase L (PMID:16234235)
• single nucleotide polymorphisms (SNPs) identified in RNASEL exons in hospitalized patients with West Nile Virus infection (PMID:16235172)
• RNASEL genetic alterations does not support a significant role in prostate cancer predisposition in Israeli Ashkenazi Jews. (PMID:16537704)
• Data suggest that the primary role of double-stranded RNA binding by the NS1A protein in virus-infected cells is to sequester dsRNA away from RNAse L. (PMID:16627618)
• Gene is associated with inherited prostatic cancer. [review] (PMID:16869093)
• A silent polymorphism in the RNASEL gene occurs more prevalently in high-risk Ashkenazi breast/ovarian cancer patients without a BRCA1/2 mutation. (PMID:16944274)
• Compared with the genotype Asp/Asp, the Glu variant at the Asp541Glu polymorphism increases prostate cancer risk by <2-fold in Caucasians, regardless of family history of the disease. (PMID:17020975)
• Report of the crystal structure of the N-terminal ankyrin repeat domain of human RNase L complexed with an activator molecule containing a 5’-phosphorylated 2’,5’-linked oligoadenylate, [(pp)p(A2’p5’)(n)A]. (PMID:17150764)
• the IFN-inducible RNase L may play an important role during stress-response through RNA-degradation and apoptosis (PMID:17200614)
• study indicated only p53 & RNASEL genotypes had significant influence on age of onset of Lynch syndrome in an additive mode of inheritance & that effects of both variants are purely additive supporting the notion (PMID:17224235)
• Positive association between higher trans-fatty acid consumption and prostate cancer may be modified by the functional RNASEL variant R462Q. (PMID:17234723)
• HuR-dependent regulation of RNase-L enhances its antiviral activity, demonstrating the functional significance of this regulation (PMID:17237228)
• the effects of oligo A synthetase/RNase on the replication cycle of parainfluenza virus type 5 (PMID:17307214)
• RNase L could have a role in cancer biology and evidence of a tumor suppressor function of RNase L has emerged from studies on the genetics of hereditary prostate cancer [review] (PMID:17400356)
• results suggest that the RNASEL Gln/Gln genotype does not play an important role in the etiology of prostate cancer in the general population (PMID:17407163)
• RNASEL has a role as a predisposition gene for prostate cancer in African Americans and Hispanic Caucasians (PMID:17908993)
• common variation in the putative prostate cancer susceptibility gene, RNASEL, or its inhibitor does not contribute significantly to prostate cancer risk in Tobago Afro-Caribbean population (PMID:18189233)
• This prospective study suggests that prostate cancer in patients with the R462Q allelic variant of the HPC1/RNASEL gene is not associated with more aggressive clinical or pathological features in radical prostatectomy specimens. (PMID:18289577)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Rnasel	ENSMUSG00000066800
rattus_norvegicus	Rnasel	ENSRNOG00000027017

Protein

Protein identifiers

2-5A-dependent ribonuclease — Q05823 (reviewed: Q05823)

Alternative names: Ribonuclease 4, Ribonuclease L

All UniProt accessions (1): Q05823

UniProt curated annotations — full annotation on UniProt →

Function. Endoribonuclease that functions in the interferon (IFN) antiviral response. In INF treated and virus infected cells, RNASEL probably mediates its antiviral effects through a combination of direct cleavage of single-stranded viral RNAs, inhibition of protein synthesis through the degradation of rRNA, induction of apoptosis, and induction of other antiviral genes. RNASEL mediated apoptosis is the result of a JNK-dependent stress-response pathway leading to cytochrome c release from mitochondria and caspase-dependent apoptosis. Therefore, activation of RNASEL could lead to elimination of virus infected cells under some circumstances. In the crosstalk between autophagy and apoptosis proposed to induce autophagy as an early stress response to small double-stranded RNA and at later stages of prolonged stress to activate caspase-dependent proteolytic cleavage of BECN1 to terminate autophagy and promote apoptosis. Might play a central role in the regulation of mRNA turnover. Cleaves 3’ of UpNp dimers, with preference for UU and UA sequences, to sets of discrete products ranging from between 4 and 22 nucleotides in length. Involved in intercellular immune signaling. Cross-activated by 2’,5’-oligoadenylates (2-5A) previously generated in RNA virus-infected cells, triggers type I interferon signaling in uninfected neighboring cells to limit local spread of infection.

Subunit / interactions. Monomer (inactive form) or homodimer. Interacts with ABCE1; this interaction inhibits the RNASEL.

Subcellular location. Cytoplasm. Mitochondrion.

Tissue specificity. Highly expressed in spleen and thymus followed by prostate, testis, uterus, small intestine, colon and peripheral blood leukocytes.

Disease relevance. Prostate cancer, hereditary, 1 (HPC1) [MIM:601518] A condition associated with familial predisposition to cancer of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Activity regulation. After binding to 2-5A (5’-phosphorylated 2’,5’-linked oligoadenylates) the homodimerization and subsequent activation occurs. Inhibited by RNASEL inhibitor ABCE1/RLI, a cytoplasmic member of the ATP-binding cassette (ABC) transporter family.

Cofactor. Manganese or magnesium. Required for optimal RNA cleavage rates.

Domain organisation. The nine ankyrin repeats also called 2-5A sensor constitute the N-terminus 2-5A binding domain. The protein kinase domain is predicted to be catalytically inactive. It allows the homodimerization. The ribonuclease domain is located in the C-terminus. A single active nuclease domain in a dimer is sufficient for ribonuclease activity.

Induction. By interferons. Virus replication in higher vertebrates is restrained by IFNs that cause cells to transcribe genes encoding antiviral proteins, such as 2’-5’ oligoadenylate synthetases (OASs). oligoadenylate synthetase is stimulated by dsRNA to produce 5’-phosphorylated, 2’-5’-linked oligoadenylates (2-5A), whose function is to activate RNASEL.

Similarity. Belongs to the protein kinase superfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q05823-1	1	yes
Q05823-2	2

RefSeq proteins (1): NP_066956* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR002110	Ankyrin_rpt	Repeat
IPR010513	KEN_dom	Domain
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily
IPR038357	KEN_sf	Homologous_superfamily
IPR042745	RNase-L_RNase	Domain

Pfam: PF00069, PF06479, PF12796, PF13857

Enzyme classification (BRENDA):

• EC 4.6.1.19 — ribonuclease T2 (BRENDA: 54 organisms, 147 substrates, 64 inhibitors, 73 Km, 16 kcat entries)

Substrate kinetics (BRENDA)

30 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
CPU	0.076–20	11
APG	0.003–1.14	4
APA	0.005–0.065	3
APC	0.025–0.13	3
APU	0.03–0.078	3
CPG	0.11–2.15	3
GPA	0.02–0.072	3
GPC	0.107–0.11	3
GPG	0.044–0.71	3
GPU	0.075–0.12	3
UPA	0.05–0.144	3
UPG	0.06–0.69	3
UPU	0.113–0.22	3
2’,3’-CCMP	0.16–0.4	2
2’,3’-CUMP	0.43–6.1	2

UniProt features (97 total): helix 43, strand 12, repeat 9, mutagenesis site 9, sequence variant 7, turn 5, region of interest 4, domain 2, splice variant 2, chain 1, zinc finger region 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
1WDY	X-RAY DIFFRACTION	1.8
4OAV	X-RAY DIFFRACTION	2.1
4G8K	X-RAY DIFFRACTION	2.4
4OAU	X-RAY DIFFRACTION	2.6
4G8L	X-RAY DIFFRACTION	2.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q05823-F1	91.96	0.83

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 684

Mutagenesis-validated functional residues (9):

Position	Phenotype
240	reduced 2-5a binding activity; almost complete loss of 2-5a binding activity; when associated with n-274.
274	reduced 2-5a binding activity; almost complete loss of 2-5a binding activity; when associated with n-240.
392	complete loss of enzymatic activity and enzyme dimerization. no change in binding to 2-5a and rna.
583	no change in enzymatic activity.
584	no change in enzymatic activity.
632	no change in enzymatic activity.
661	complete loss of enzymatic activity.
667	complete loss of enzymatic activity. no change in 2-5a binding and enzyme dimerization.
672	complete loss of enzymatic activity. no change in 2-5a binding activity and enzyme dimerization.

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-8983711	OAS antiviral response
R-HSA-909733	Interferon alpha/beta signaling
R-HSA-1169410	Antimicrobial mechanism of IFN-stimulated genes
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-168256	Immune System
R-HSA-913531	Interferon Signaling

MSigDB gene sets: 221 (showing top): GOBP_RIBOSOME_BIOGENESIS, GOBP_CARBOHYDRATE_TRANSPORT, GOMF_ENDONUCLEASE_ACTIVITY, GOMF_RNA_NUCLEASE_ACTIVITY, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, MODULE_255, GOMF_NUCLEASE_ACTIVITY, MODULE_64, GOBP_NEGATIVE_REGULATION_OF_VIRAL_PROCESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, MODULE_317, TAKADA_GASTRIC_CANCER_COPY_NUMBER_DN, GOBP_POSITIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION

GO Biological Process (12): rRNA processing (GO:0006364), RNA processing (GO:0006396), mRNA processing (GO:0006397), protein phosphorylation (GO:0006468), regulation of mRNA stability (GO:0043488), negative regulation of viral genome replication (GO:0045071), fat cell differentiation (GO:0045444), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of D-glucose import across plasma membrane (GO:0046326), defense response to virus (GO:0051607), regulation of gene expression (GO:0010468), regulation of RNA metabolic process (GO:0051252)

GO Molecular Function (15): RNA binding (GO:0003723), RNA endonuclease activity (GO:0004521), RNA nuclease activity (GO:0004540), protein kinase activity (GO:0004672), ATP binding (GO:0005524), zinc ion binding (GO:0008270), hydrolase activity (GO:0016787), rRNA binding (GO:0019843), identical protein binding (GO:0042802), ribonucleoprotein complex binding (GO:0043021), nucleotide binding (GO:0000166), nuclease activity (GO:0004518), endonuclease activity (GO:0004519), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (5): mitochondrial matrix (GO:0005759), cytosol (GO:0005829), nuclear matrix (GO:0016363), cytoplasm (GO:0005737), mitochondrion (GO:0005739)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Interferon Signaling	2
Antimicrobial mechanism of IFN-stimulated genes	1
Immune System	1
Cytokine Signaling in Immune system	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
RNA processing	2
gene expression	2
nuclease activity	2
cytoplasm	2
rRNA metabolic process	1
ribosome biogenesis	1
RNA biosynthetic process	1
primary metabolic process	1
mRNA metabolic process	1
phosphorylation	1
protein modification process	1
regulation of RNA stability	1
regulation of mRNA catabolic process	1
viral genome replication	1
regulation of viral genome replication	1
negative regulation of viral process	1
cell differentiation	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
positive regulation of D-glucose transmembrane transport	1
regulation of D-glucose import across plasma membrane	1
D-glucose import across plasma membrane	1
defense response	1
response to virus	1
regulation of macromolecule biosynthetic process	1
RNA metabolic process	1
regulation of nucleobase-containing compound metabolic process	1
regulation of macromolecule metabolic process	1
nucleic acid binding	1
endonuclease activity	1
RNA nuclease activity	1
catalytic activity, acting on RNA	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
transition metal ion binding	1

Protein interactions and networks

STRING

6792 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RNASEL	OAS1	P00973	924
RNASEL	ABCE1	P61221	918
RNASEL	OASL	Q15646	915
RNASEL	OAS3	Q9Y6K5	908
RNASEL	EIF2AK2	P19525	902
RNASEL	OAS2	P29728	859
RNASEL	RIGI	O95786	835
RNASEL	IFIH1	Q9BYX4	809
RNASEL	ELAC2	Q9BQ52	759
RNASEL	ANG	P03950	740
RNASEL	PDE12	Q6L8Q7	718
RNASEL	IFNB1	P01574	705
RNASEL	IFNAR2	P48551	693
RNASEL	MTIF2	P46199	688
RNASEL	MX1	P20591	688

IntAct

45 interactions, top by confidence:

A	B	Type	Score
HIF1AN	APBA3	psi-mi:“MI:0914”(association)	0.850
HIF1AN	GMDS	psi-mi:“MI:0914”(association)	0.640
LPAR4	POTEF	psi-mi:“MI:0914”(association)	0.530
SLC15A1	METTL15	psi-mi:“MI:0914”(association)	0.530
IL13RA2	METTL15	psi-mi:“MI:0914”(association)	0.530
SYP	APBB1	psi-mi:“MI:0914”(association)	0.530
RNASEL	IQGAP1	psi-mi:“MI:0914”(association)	0.500
RNASEL	IQGAP1	psi-mi:“MI:0915”(physical association)	0.500
TP53	MDM2	psi-mi:“MI:0914”(association)	0.350
HIF1AN	CNOT1	psi-mi:“MI:0914”(association)	0.350
ST8SIA4	NRP1	psi-mi:“MI:0914”(association)	0.350
SYP	APBB1	psi-mi:“MI:0914”(association)	0.350
DOCK5	DPYSL4	psi-mi:“MI:0914”(association)	0.350
SLC37A3	CYB5R3	psi-mi:“MI:0914”(association)	0.350
HIF1AN	ST13	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
RNASEL	UNC119B	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
SV2A	ILVBL	psi-mi:“MI:0914”(association)	0.350
S100A2	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
ST8SIA4	FAM234B	psi-mi:“MI:0914”(association)	0.350
PTH2R	METTL15	psi-mi:“MI:0914”(association)	0.350
PRKY	METTL15	psi-mi:“MI:0914”(association)	0.350
SLC18A2	UBXN8	psi-mi:“MI:0914”(association)	0.350
HNRNPCL2	SMCHD1	psi-mi:“MI:0914”(association)	0.350

BioGRID (52): TCF12 (Two-hybrid), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-RNA), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-MS), RNASEL (Affinity Capture-MS)

ESM2 similar proteins: A0A1L8GXY4, A4IIK1, A6NGH8, B0R160, C6FG12, E7F654, O12990, O19064, O60674, O62471, P32019, Q05823, Q09178, Q1EHT7, Q1L8H0, Q20CR4, Q2T9W8, Q32KX5, Q38SD2, Q3TX51, Q3UHC2, Q3UV48, Q3V1N1, Q4VSN2, Q4VSN5, Q5RB23, Q5XUN4, Q62120, Q62689, Q641X1, Q6GLE8, Q6GM71, Q6X9E4, Q6XUX3, Q75R65, Q7KLI1, Q86V97, Q86X40, Q8BWR4, Q8C4V4

Diamond homologs: A0A072VIM5, A0A0K0PU92, A2CIR7, B9DHT4, C9JJ37, E7BQV0, G3LSH3, G8GTN7, Q05823, Q0JJ01, Q2HW56, Q2QXZ2, Q2RAQ5, Q5D0W8, Q5ICL9, Q5XIU1, Q75HA6, Q8L746, Q96BM1, Q96DX5, Q99LJ2, Q9FDY4, Q9M1I7, Q9SZI3, Q9ZVC2, S4VGD0, Q5R4S6, Q8R179, Q9N010, Q9NVX7, A0M8T3, A1X154, A4D7T3, C9JTQ0, Q00PJ3, Q05921, Q07DV3, Q07DX6, Q07DY6, Q07DZ7

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
BRCA1	“up-regulates quantity by expression”	RNASEL	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

169 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	2
Uncertain significance	136
Likely benign	12
Benign	8

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
13005	NM_021133.4(RNASEL):c.3G>A (p.Met1Ile)	Pathogenic
2445339	NM_021133.4(RNASEL):c.1115C>A (p.Ala372Asp)	Likely pathogenic
2445376	NM_021133.4(RNASEL):c.1469A>G (p.Asn490Ser)	Likely pathogenic

SpliceAI

1112 predictions. Top by Δscore:

Variant	Effect	Δscore
1:182576251:CTTA:C	donor_gain	1.0000
1:182576254:A:AC	donor_gain	1.0000
1:182576254:ACTTT:A	donor_loss	1.0000
1:182576255:C:CA	donor_gain	1.0000
1:182576255:CT:C	donor_gain	1.0000
1:182576255:CTT:C	donor_gain	1.0000
1:182576255:CTTT:C	donor_gain	1.0000
1:182576255:CTTTT:C	donor_gain	1.0000
1:182576385:TTAAT:T	acceptor_gain	1.0000
1:182576386:TAAT:T	acceptor_gain	1.0000
1:182576386:TAATC:T	acceptor_loss	1.0000
1:182576387:AAT:A	acceptor_gain	1.0000
1:182576387:AATC:A	acceptor_loss	1.0000
1:182576388:AT:A	acceptor_gain	1.0000
1:182576389:TCT:T	acceptor_loss	1.0000
1:182576390:C:CC	acceptor_gain	1.0000
1:182576390:CTAA:C	acceptor_loss	1.0000
1:182582052:CCT:C	donor_gain	1.0000
1:182582256:GTCC:G	acceptor_loss	1.0000
1:182582257:TCCT:T	acceptor_loss	1.0000
1:182576391:T:A	acceptor_loss	0.9900
1:182579772:T:A	donor_gain	0.9900
1:182582048:CTTA:C	donor_loss	0.9900
1:182582049:TTA:T	donor_loss	0.9900
1:182582050:TA:T	donor_loss	0.9900
1:182582051:A:AC	donor_gain	0.9900
1:182582052:C:CC	donor_gain	0.9900
1:182582052:C:CT	donor_loss	0.9900
1:182582052:CCTCT:C	donor_gain	0.9900
1:182582255:GGTC:G	acceptor_gain	0.9900

AlphaMissense

4931 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:182586429:G:C	F126L	0.985
1:182586429:G:T	F126L	0.985
1:182586431:A:G	F126L	0.985
1:182581236:A:G	W632R	0.983
1:182581236:A:T	W632R	0.983
1:182576295:C:G	R667P	0.979
1:182582140:A:G	L562P	0.970
1:182586611:C:G	A66P	0.970
1:182581234:C:A	W632C	0.969
1:182581234:C:G	W632C	0.969
1:182585631:C:A	K392N	0.965
1:182585631:C:G	K392N	0.965
1:182586413:C:G	A132P	0.965
1:182582245:A:G	L527P	0.964
1:182585639:C:G	A390P	0.962
1:182576310:A:G	L662P	0.961
1:182575530:A:C	F696L	0.958
1:182575530:A:T	F696L	0.958
1:182575532:A:G	F696L	0.958
1:182581243:A:C	F629L	0.957
1:182581243:A:T	F629L	0.957
1:182581245:A:G	F629L	0.957
1:182585625:G:C	F394L	0.956
1:182585625:G:T	F394L	0.956
1:182585627:A:G	F394L	0.956
1:182586424:G:T	A128D	0.956
1:182575522:A:G	L699P	0.955
1:182582066:A:G	W587R	0.955
1:182582066:A:T	W587R	0.955
1:182586629:A:G	W60R	0.955

dbSNP variants (sampled 300 via entrez): RS1000067288 (1:182589895 A>G), RS1000125889 (1:182574262 C>T), RS1000280983 (1:182590620 C>T), RS1000336757 (1:182590119 C>A,T), RS1000377925 (1:182581723 A>C,G,T), RS1000396228 (1:182582993 A>T), RS1000428041 (1:182576827 G>A,T), RS1000707032 (1:182585252 T>C), RS1000800351 (1:182576976 A>C), RS1000943502 (1:182588679 C>A), RS1001398265 (1:182573965 T>C), RS1001477950 (1:182588391 T>C), RS1001519295 (1:182579515 G>A,C,T), RS1001742513 (1:182577367 A>G), RS1001870470 (1:182573586 C>T)

Disease associations

OMIM: gene MIM:180435 | disease phenotypes: MIM:601518, MIM:167000

GenCC curated gene-disease

Disease	Classification	Inheritance
multisystem inflammatory syndrome in children and adults	Moderate	Autosomal recessive
prostate cancer, hereditary, 1	Limited	Autosomal dominant

Mondo (4): prostate cancer (MONDO:0008315), prostate cancer, hereditary, 1 (MONDO:0011098), ovarian cancer (MONDO:0008170), multisystem inflammatory syndrome in children and adults (MONDO:0035375)

Orphanet (2): Familial prostate cancer (Orphanet:1331), Rare ovarian cancer (Orphanet:213500)

HPO phenotypes

3 total (3 of 3 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0003581	Adult onset
HP:0012125	Prostate cancer

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001860_11	Multiple sclerosis	6.000000e-09
GCST003429_2	Morning vs. evening chronotype	7.000000e-18

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D010051	Ovarian Neoplasms	C04.588.322.455; C12.050.351.500.056.630.705; C12.050.351.937.418.685; C12.100.250.056.630.705; C12.900.418.685; C19.344.410; C19.391.630.705
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3575 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

61 potent at pChembl≥5 of 81 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.40	Kd	0.04	nM	CHEMBL404038
9.89	EC50	0.13	nM	CHEMBL402676
9.82	EC50	0.15	nM	CHEMBL414948
9.70	EC50	0.2	nM	CHEMBL414948
9.70	EC50	0.2	nM	CHEMBL402676
9.68	EC50	0.21	nM	CHEMBL414948
9.66	Kd	0.22	nM	CHEMBL404038
9.62	EC50	0.24	nM	CHEMBL214603
9.52	EC50	0.3	nM	CHEMBL214603
9.35	EC50	0.45	nM	CHEMBL3817920
9.30	EC50	0.5	nM	CHEMBL404038
9.17	EC50	0.68	nM	CHEMBL405496
9.15	EC50	0.7	nM	CHEMBL384725
9.14	IC50	0.72	nM	CHEMBL214603
9.10	EC50	0.8	nM	CHEMBL405496
9.08	EC50	0.84	nM	CHEMBL384725
8.96	IC50	1.1	nM	CHEMBL414948
8.64	EC50	2.3	nM	CHEMBL601938
8.62	EC50	2.4	nM	CHEMBL3818262
8.60	EC50	2.5	nM	CHEMBL601938
8.60	EC50	2.5	nM	CHEMBL591446
8.59	IC50	2.6	nM	CHEMBL402676
8.57	EC50	2.7	nM	CHEMBL3819183
8.40	EC50	4	nM	CHEMBL410213
8.38	EC50	4.2	nM	CHEMBL2058766
8.34	EC50	4.6	nM	CHEMBL410213
8.21	EC50	6.1	nM	CHEMBL2414867
8.19	EC50	6.5	nM	CHEMBL2058765
8.14	IC50	7.3	nM	CHEMBL414948
8.01	EC50	9.7	nM	CHEMBL601940
7.89	EC50	12.9	nM	CHEMBL601940
7.89	IC50	13	nM	CHEMBL414948
7.82	EC50	15	nM	CHEMBL2058764
7.80	EC50	16	nM	CHEMBL407239
7.77	EC50	17	nM	CHEMBL601940
7.72	EC50	19.1	nM	CHEMBL2414866
7.70	IC50	20	nM	CHEMBL414948
7.69	EC50	20.3	nM	CHEMBL3818726
7.62	IC50	24	nM	CHEMBL405496
7.52	EC50	30	nM	CHEMBL407239
7.28	EC50	53	nM	CHEMBL2057900
7.24	IC50	57	nM	CHEMBL384725
7.08	EC50	84	nM	CHEMBL3819262
6.98	IC50	105	nM	CHEMBL410213
6.87	EC50	134	nM	CHEMBL3818137
6.70	EC50	200	nM	CHEMBL2058187
6.68	IC50	210	nM	CHEMBL1159914
6.62	EC50	241	nM	CHEMBL2414865
6.52	EC50	300	nM	CHEMBL2058191
6.52	EC50	300	nM	CHEMBL2057902

PubChem BioAssay actives

60 with measured affinity, of 242 total; 33 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate	319035: Binding affinity to human recombinant RNase L	kd	<0.0001	uM
[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate	197821: Activation of purified recombinant human Ribonuclease L by the compound was measured as degradation of poly (U) 3’[32P]p5’C3’p	ec50	0.0001	uM
[(2R,3R,4R,5R)-4-[[(2R,3S,4R,5R)-5-(6-amino-2-methylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate	197821: Activation of purified recombinant human Ribonuclease L by the compound was measured as degradation of poly (U) 3’[32P]p5’C3’p	ec50	0.0001	uM
[[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-4-[[(2R,3S,4R,5R)-5-(6-amino-2-methylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate	197821: Activation of purified recombinant human Ribonuclease L by the compound was measured as degradation of poly (U) 3’[32P]p5’C3’p	ec50	0.0002	uM
[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-4-[[(2R,3S,4R,5R)-5-(6-amino-8-methylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3R,4R,5R)-2-(5-fluoro-2,4-dioxopyrimidin-1-yl)-4-hydroxy-5-methyloxolan-3-yl] hydrogen phosphate	1309499: Induction of recombinant human RNase L activity expressed in Escherichia coli using F-5’-r(C11U2C7)-3’ as substrate by polyacrylamide gel electrophoresis	ec50	0.0004	uM
[[(2R,3R,4R,5R)-5-(6-amino-2-methylpurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate	197821: Activation of purified recombinant human Ribonuclease L by the compound was measured as degradation of poly (U) 3’[32P]p5’C3’p	ec50	0.0007	uM
[(2R,3R,4R,5R)-2-(6-amino-2-methylpurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] [(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl hydrogen phosphate	197820: Activation of purified recombinant human Ribonuclease L by the compound was measured as degradation of [32P]-pC11U2C7	ec50	0.0007	uM
[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-4-[[(2R,3S,4R,5R)-5-(6-amino-8-methylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate	1309499: Induction of recombinant human RNase L activity expressed in Escherichia coli using F-5’-r(C11U2C7)-3’ as substrate by polyacrylamide gel electrophoresis	ec50	0.0023	uM
[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-4-[[(2R,3S,4R,5R)-5-(6-amino-8-methylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3R,4R,5R)-2-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate	1309499: Induction of recombinant human RNase L activity expressed in Escherichia coli using F-5’-r(C11U2C7)-3’ as substrate by polyacrylamide gel electrophoresis	ec50	0.0024	uM
[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-4-[[(2R,3S,4R,5R)-5-(6-amino-8-methylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate	457411: Inhibition of human RNaseL ANK domain expressed in Escherichia coli assessed as 5’ flurescein-r(C11U2C7)-3’ RNA cleavage	ec50	0.0025	uM
[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-4-[[(2R,3S,4R,5R)-5-(6-amino-8-methylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3R,4R,5R)-2-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate	1309499: Induction of recombinant human RNase L activity expressed in Escherichia coli using F-5’-r(C11U2C7)-3’ as substrate by polyacrylamide gel electrophoresis	ec50	0.0027	uM
[[(2R,3R,4R,5R)-5-(6-amino-2-methylpurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-amino-2-methylpurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-amino-2-methylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate	197820: Activation of purified recombinant human Ribonuclease L by the compound was measured as degradation of [32P]-pC11U2C7	ec50	0.0040	uM
[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxy-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxymethyl]phosphinic acid	671695: Activation of human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-rC11-UU-C7-BHQ2 as substrate by FRET assay	ec50	0.0042	uM
[[(2R,3R,4R,5R)-5-(6-aminopurin-7-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-7-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-7-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-7-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate	763856: Activation of human recombinant RNase L endonuclease activity using 6-FAM-UUA UCA AAU UCU UAU UUG CCC CAU UUU UUU GGU UUA-BHQ-1 as substrate assessed as substrate cleavage measured for 50 mins by FRET assay	ec50	0.0061	uM
[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxy-[[(2R,3S,4S,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxymethyl]phosphinic acid	671695: Activation of human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-rC11-UU-C7-BHQ2 as substrate by FRET assay	ec50	0.0065	uM
[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate	457411: Inhibition of human RNaseL ANK domain expressed in Escherichia coli assessed as 5’ flurescein-r(C11U2C7)-3’ RNA cleavage	ec50	0.0097	uM
[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxy-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxymethyl]phosphinic acid	671695: Activation of human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-rC11-UU-C7-BHQ2 as substrate by FRET assay	ec50	0.0150	uM
[(2R,3R,4R,5R)-5-(6-amino-2-methylpurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-amino-2-methylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2R,3R,4R,5R)-2-(6-amino-2-methylpurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate	197821: Activation of purified recombinant human Ribonuclease L by the compound was measured as degradation of poly (U) 3’[32P]p5’C3’p	ec50	0.0160	uM
[(2R,3S,4R,5R)-5-(6-aminopurin-7-yl)-2-[[[(2R,3R,4R,5R)-2-(6-aminopurin-7-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-7-yl)-4-(2,2-dimethylpropanoyloxymethoxy)-5-[[hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-(2,2-dimethylpropanoyloxymethoxy)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxymethyl 2,2-dimethylpropanoate	763856: Activation of human recombinant RNase L endonuclease activity using 6-FAM-UUA UCA AAU UCU UAU UUG CCC CAU UUU UUU GGU UUA-BHQ-1 as substrate assessed as substrate cleavage measured for 50 mins by FRET assay	ec50	0.0191	uM
[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-4-[[(2R,3S,4R,5R)-5-(6-amino-8-methylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate	1309499: Induction of recombinant human RNase L activity expressed in Escherichia coli using F-5’-r(C11U2C7)-3’ as substrate by polyacrylamide gel electrophoresis	ec50	0.0203	uM
[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxymethylphosphonic acid	671695: Activation of human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-rC11-UU-C7-BHQ2 as substrate by FRET assay	ec50	0.0530	uM
[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2R,3R,4R,5R)-2-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate	1309499: Induction of recombinant human RNase L activity expressed in Escherichia coli using F-5’-r(C11U2C7)-3’ as substrate by polyacrylamide gel electrophoresis	ec50	0.0840	uM
[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-4-[[(2R,3S,4R,5R)-5-(6-amino-8-methylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate	1309499: Induction of recombinant human RNase L activity expressed in Escherichia coli using F-5’-r(C11U2C7)-3’ as substrate by polyacrylamide gel electrophoresis	ec50	0.1340	uM
[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxymethyl-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]phosphinic acid	671695: Activation of human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-rC11-UU-C7-BHQ2 as substrate by FRET assay	ec50	0.2000	uM
[4-(6-aminopurin-9-yl)-3-[[4-(6-aminopurin-9-yl)-2,3-dihydroxycyclopentyl]methoxy-hydroxyphosphoryl]oxy-2-hydroxycyclopentyl]methyl [5-(6-aminopurin-9-yl)-2-hydroxy-3-(phosphonooxymethyl)cyclopentyl] hydrogen phosphate	166870: Inhibitory activity to prevent binding of added ppp5’A2’p5’A2’pA2’p5’A3’[32P]p5’ (c3 label) to RNase L in human Daudi lymphoblastoid cells	ic50	0.2100	uM
[(2R,3S,4R,5R)-5-(6-aminopurin-7-yl)-2-[[[(2R,3R,4R,5R)-2-(6-aminopurin-7-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-7-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-7-yl)-4-(2,2-dimethylpropanoyloxymethoxy)-5-[[hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-(2,2-dimethylpropanoyloxymethoxy)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-(2,2-dimethylpropanoyloxymethoxy)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxymethyl 2,2-dimethylpropanoate	763856: Activation of human recombinant RNase L endonuclease activity using 6-FAM-UUA UCA AAU UCU UAU UUG CCC CAU UUU UUU GGU UUA-BHQ-1 as substrate assessed as substrate cleavage measured for 50 mins by FRET assay	ec50	0.2410	uM
[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-[[(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl]oxymethyl]phosphinic acid	671695: Activation of human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-rC11-UU-C7-BHQ2 as substrate by FRET assay	ec50	0.3000	uM
[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxymethyl-[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxyphosphinic acid	671695: Activation of human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-rC11-UU-C7-BHQ2 as substrate by FRET assay	ec50	0.3000	uM
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxymethylphosphonic acid	671695: Activation of human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-rC11-UU-C7-BHQ2 as substrate by FRET assay	ec50	0.3000	uM
[(2R,3S,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxymethyl-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]phosphinic acid	671695: Activation of human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-rC11-UU-C7-BHQ2 as substrate by FRET assay	ec50	1.0000	uM
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxymethyl-[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-[[[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl]oxyphosphinic acid	671695: Activation of human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-rC11-UU-C7-BHQ2 as substrate by FRET assay	ec50	1.0000	uM
[(2R,3R,4S,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methoxymethylphosphonic acid	671695: Activation of human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-rC11-UU-C7-BHQ2 as substrate by FRET assay	ec50	1.0000	uM
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one	1820774: Inhibition of full length H-RNAase L expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate incubated for 15 min in presence of 5 nM 2-5A for 15 mins by Coomassie staining based SDS-PAGE analysis	ic50	1.3200	uM

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
2’,5’-oligoadenylate	increases uptake, affects binding, increases activity, increases expression	2
Silicon Dioxide	decreases expression, increases expression	2
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
pirinixic acid	decreases expression, increases activity, affects binding	1
bisphenol A	increases expression	1
trichostatin A	increases expression	1
sodium arsenite	increases expression	1
hydroquinone	decreases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, increases oxidation	1
CGP 52608	affects binding, increases reaction	1
erastin	increases expression, increases reaction	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Acrolein	increases oxidation, increases abundance, affects cotreatment	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Air Pollutants, Occupational	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Calcitriol	increases expression, affects cotreatment	1
Camptothecin	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Doxycycline	increases expression, increases reaction	1
Glucose	affects binding, increases activity, increases uptake	1
Nickel	decreases expression	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Testosterone	increases expression, affects cotreatment	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1
Valproic Acid	increases expression	1
Cyclosporine	decreases expression	1

ChEMBL screening assays

43 unique, capped per target: 42 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1065130	Binding	Inhibition of human RNaseL ANK domain expressed in Escherichia coli assessed as 5’ flurescein-r(C11U2C7)-3’ RNA cleavage	5’-O-dephosphorylated 2’,5’-oligoadenylate (2-5A) with 8-methyladenosine at the 2’-terminus activates human RNase L. — Bioorg Med Chem Lett
CHEMBL2060469	Functional	Antagonist activity at human RNase L expressed in Escherichia coli BL21 (DE3) cells assessed as RNA cleavage using Cy5-C11-rUU-C7-BHQ2 as substrate by FRET assay in presence of natural activator pAAAA	Activation of human RNase L by 2’- and 5’-O-methylphosphonate-modified oligoadenylates. — Bioorg Med Chem Lett

Cellosaurus cell lines

4 cell lines: 3 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7HC	Ubigene HEK293T RNASEL KO	Transformed cell line	Female
CVCL_F1ME	HyCyte A-549 KO-hRNASEL	Cancer cell line	Male
CVCL_TJ21	HAP1 RNASEL (-) 1	Cancer cell line	Male
CVCL_TJ22	HAP1 RNASEL (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer